Exelixis | EXEL - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics USD 349.66M 12.86M 2026-06
Amgen USD 95.64B 3.14B 2026-06
AstraZeneca USD 119.92B 4.09B 2026-09
Bayer EUR 107.29B 659M 2026-06
BioMarin Pharmaceutical USD 11.57B 154.21M 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Cytokinetics USD 1.92B 651.07M 2026-06
Eisai JPY 1.56T 108.98B 2026-06
Eli Lilly USD 148.07B 5.79B 2026-09
Exelixis USD 2.51B 19.26M 2026-09
Genmab DKK 12.52B 139M 2026-06
Glaxosmithkline GBP 71.7B 8.83B 2026-09
Incyte USD 7.29B 585.39M 2026-09
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 129.8B 1.12B 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.63B 268.3M 2026-09
Novartis USD 117.15B 4.88B 2026-09
Pfizer USD 204.54B 3.41B 2026-09
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sanofi EUR 129.06B 1.04B 2026-06
Takeda JPY 15.27T 391.77B 2026-09
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Xencor USD 724.96M 11.89M 2026-06